ArticleHaematologica2026

Three-year safety, efficacy, and renal outcomes of mitapivat treatment in sickle cell disease: results from the phase 2 open-label study.

Geoffrey Z L Kuppens et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.